Description

Encorat (valproic acid) Coated Tablets with Prolonged Release 300 mg. №30

Ingredients

Active ingredient: Valproic acid 300 mg.
Other ingredients: cellulose, povidone, talc, methacrylic acid copolymer, triethyl citrate, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).

Dosage

Recommended dosage: The usual starting dose is 300 mg once daily. Dosage may be adjusted as needed under the supervision of a healthcare provider.

Indications

Encorat (valproic acid) coated tablets are indicated for the treatment of epilepsy, bipolar disorder, and migraine prophylaxis.

Contraindications

Do not use Encorat tablets if:

• You are allergic to valproic acid or any other ingredients in the product.
• You have a history of acute liver failure.
• You have a urea cycle disorder.

Directions

Take Encorat tablets orally with or without food, as directed by your healthcare provider. Do not crush or chew the tablets.

Scientific Evidence

Encorat (valproic acid) coated tablets have been extensively studied for their efficacy in the management of epilepsy and bipolar disorder. Clinical trials have shown that prolonged-release formulations of valproic acid offer better tolerability and reduced side effects compared to immediate-release formulations.

Additional Information

It is important to follow the prescribed dosage and not to discontinue the medication abruptly, as it may lead to withdrawal symptoms or a recurrence of symptoms. Regular monitoring of liver function tests is recommended during treatment with valproic acid.

Valproic acid exerts its pharmacological effects by increasing the levels of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity. This action helps in controlling seizures and stabilizing mood in patients with bipolar disorder.

Comparative studies have shown that Encorat tablets with prolonged release provide a more consistent drug delivery profile, leading to improved patient compliance and better symptom control compared to traditional immediate-release formulations.